How do we put meaning into meaningful benefit? Perspectives from the lived experience
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-04 · 11 (2)
DOI: 10.1002/trc2.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 14.05.2025. Verfasst von Russ Paulsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: UsAgainstAlzheimer's Washington District of Columbia USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Meaningful benefit is a much‐debated concept in Alzheimer's disease (AD). Research to date has primarily focused on change thresholds that are anchored in clinicians’ or care partners’ impressions; however, these thresholds are not inherently meaningful to people living with AD (PLWAD) and may not take their perspectives into account. By overlaying the lived experience of AD through the eyes of individual PLWAD and their care partners with clinical outcomes, we offer an important framework in which to consider meaningful benefit in terms of symptoms, functioning, and outcomes. The PLWAD and care partner interviews and surveys of the What Matters Most (WMM) research program have identified treatment‐related needs, preferences, and priorities of people at risk of or living with AD and their care partners across the AD continuum. A WMM conceptual model of disease—created and refined through interviews with PLWAD and care partners across the AD severity spectrum—includes 50 concepts across six domains (social life/activities, thought processing, communication, daily activities, mood/emotion, and general independence) considered important to all PLWAD and care partners. From the PLWAD and care partner perspectives, an increase in time to the onset, development, or worsening of the symptoms in any of these meaningful concepts was considered a meaningful benefit. No single commonly used clinical outcome assessment captures all concepts of importance, nor the importance of time in AD; considering the lived experience and priorities of individuals affected by AD is crucial to put the “meaning” in “meaningful.”
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UsAgainstAlzheimer's Washington District of Columbia USA.
- RTI Health Solutions Durham North Carolina USA.
- Faegre Drinker Consulting Washington District of Columbia USA.
- Department of Neurology Mayo Clinic Rochester Minnesota USA.
- Department of Brain Health, Kirk Kerkorian School of Medicine Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas (UNLV) Las Vegas Nevada USA.
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- NIA NIH HHS
- UsAgainstAlzheimer's
Zitieren
APA
Paulsen, R., Romano, C. D., Frangiosa, T., Mordin, M., Dardis, G. J., DiBenedetti, D., Petersen, R. C., & Cummings, J. L. (2025). How do we put meaning into meaningful benefit? Perspectives from the lived experience. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2). https://doi.org/10.1002/trc2.70095
Vancouver
Paulsen R, Romano CD, Frangiosa T, Mordin M, Dardis GJ, DiBenedetti D, et al. How do we put meaning into meaningful benefit? Perspectives from the lived experience. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(2). doi:10.1002/trc2.70095
BibTeX
@article{Paulsen2025,
author = {Paulsen, Russ and Romano, Carla DeMuro and Frangiosa, Terry and Mordin, Margaret and Dardis, Gabrielle J and DiBenedetti, Dana and Petersen, Ronald C and Cummings, Jeffrey L},
title = {How do we put meaning into meaningful benefit? Perspectives from the lived experience},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2025},
volume = {11},
number = {2},
doi = {10.1002/trc2.70095}
}
EUVIMED